Baudax Bio Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Gerri Henwood
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 5yrs |
| CEO ownership | 0.004% |
| Management average tenure | 1.1yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Baudax Bio stock down after pricing $6.2M equity offering
Aug 30Baudax Bio to get US patent linked to pain drug Anjeso
Aug 22Baudax Bio GAAP EPS of -$1.05 beats by $0.22, revenue of $0.3M
Aug 11Cosette Pharmaceuticals appoints Rick Casten as CFO
Jul 06Baudax Bio: Looking For A Turnaround In Strong COVID-19 Headwinds
Sep 09A First Look At Baudax Bio
May 30Baudax Bio EPS misses by $0.08, misses on revenue
May 05Baudax Bio's Anjeso shows efficacy in pain management for total knee arthroplasty
Apr 26Have Insiders Been Buying Baudax Bio, Inc. (NASDAQ:BXRX) Shares?
Feb 17
Baudax Bio EPS of $0.62
Nov 09Baudax Bio: Why I'm Catching This Falling Knife
Nov 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$61m |
| Mar 31 2023 | n/a | n/a | -US$58m |
| Dec 31 2022 | US$663k | US$618k | -US$59m |
| Sep 30 2022 | n/a | n/a | US$13m |
| Jun 30 2022 | n/a | n/a | -US$67k |
| Mar 31 2022 | n/a | n/a | -US$11m |
| Dec 31 2021 | US$2m | US$618k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$38m |
| Mar 31 2021 | n/a | n/a | -US$53m |
| Dec 31 2020 | US$603k | US$309k | -US$76m |
| Sep 30 2020 | n/a | n/a | -US$66m |
| Jun 30 2020 | n/a | n/a | -US$88m |
| Mar 31 2020 | n/a | n/a | -US$69m |
| Dec 31 2019 | US$3m | US$46k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$51m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$2m | US$599k | -US$74m |
Compensation vs Market: Insufficient data to establish whether Gerri's total compensation is reasonable compared to companies of similar size in the US market.
Compensation vs Earnings: Gerri's compensation has been consistent with company performance over the past year.
CEO
Gerri Henwood (72 yo)
5yrs
Tenure
US$663,224
Compensation
Dr. Geraldine A. Henwood, also known as Gerri, Ph D., has been the President, Chief Executive Officer and Director of Baudax Bio Inc. since 2019. She has been the Chief Development Officer of Iomab-B at Ac...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5yrs | US$663.22k | 0.0037% $ 0.002 | |
| Vice President of Financial Planning & Analysis | less than a year | no data | no data | |
| Consultant & Principle Accounting Officer | less than a year | no data | no data | |
| Chief Scientific Officer & Director | 1.3yrs | no data | no data |
1.1yrs
Average Tenure
53yo
Average Age
Experienced Management: BXRX.Q's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 5yrs | US$663.22k | 0.0037% $ 0.002 | |
| Chief Scientific Officer & Director | 1.3yrs | no data | no data | |
| Independent Director | 5yrs | US$95.11k | 0.0022% $ 0.001 | |
| Independent Chairman | 5.8yrs | US$113.59k | 0.0020% $ 0.001 | |
| Independent Director | 4.3yrs | US$89.97k | 0.0020% $ 0.001 | |
| Independent Director | 5.8yrs | US$99.97k | 0.0020% $ 0.001 | |
| Independent Director | 4.3yrs | US$82.47k | 0.0020% $ 0.001 |
5.0yrs
Average Tenure
72yo
Average Age
Experienced Board: BXRX.Q's board of directors are considered experienced (5 years average tenure).